Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Eurovision Song Contest changes voting rules after controversial allegations against Israel - 21st human missions to Mars should hunt for signs of life, report says
- 3Vote In favor of Your Favored Distributed computing Administration
- 4Figure out How to Use the Experience of a Fender bender Legal counselor for Your Potential benefit
- 5Research institutions tout the value of scholarship that crosses disciplines – but academia pushes interdisciplinary researchers out
- Why some African countries are prone to military takeovers
- Trouvez La Carte De Cr\u00e9dit Id\u00e9ale Pour Vos Besoins En Belgique
- New movies to watch this weekend: See 'We Bury the Dead' in theaters, rent 'Wicked: For Good,' stream 'The Unbreakable Boy' on Starz
- Figure out How to Reveal Stowed away Open Record Rewards
- How did I get my own unique set of fingerprints?
- From Educational Loans to Obligation Free: Independence from the rat race Accomplished
- Dominating Monetary Administration: A Bit by bit Manual for Making an Individual Financial plan
- We may be witnessing the messy death of a star in real time
- FDA updates risk classification for voluntary shredded cheese recall
